The stock's fall snapped a three-day winning streak.

Like its competitors, Google continues to experiment with low- and no-code tools that harness agentic AI for business ...

Among the FDA’s pending decisions for this quarter are Vertex’s non-opioid pain drug and Sanofi’s RNA interference therapy ...

Arish Global Services, the all-in-one solution for web lead generation based in the UK, announced today its partnership with Vertex Global Services ...

The startup is developing a kind of macrocyles, which share strengths of both small molecules and biologics, to make oral ...

Obsidian Therapeutics, Inc., a clinical-stage biotechnology company pioneering engineered cell and gene therapies, today announced that Chief Executive Officer, Madan Jagasia, M.D., will present at ...

Researchers have identified six new biomarkers that could detect kidney injury faster and with more sensitivity, advancing safer drug development and improving health outcomes for patients. The new ...

A first-in-class pain med and blockbusters with new indications are just a few of the possible approvals to keep an eye on in ...

By the end of March, the regulator could clear a highly anticipated pain drug from Vertex and a heart drug that’s critical to Alnylam’s future.

Drug-induced kidney injury, or nephrotoxicity, is a common complication in clinical medicine that happens when drugs damage ...

A company’s return on average assets sheds light on how well its management team has allocated investors’ money.

Russia and other hostile states have become increasingly brazen in adopting “gray zone” attacks against Europe and the United States, leaving defense officials with a dilemma: How to respond ...